Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 1:16 AM
Ignite Modification Date:
2025-12-25 @ 11:25 PM
NCT ID:
NCT02880293
Group ID:
EG000
Title:
Patients Will Undergo Donor/Recipient Bone Marrow
Description:
All patients will undergo haploidentical, allogeneic hematopoietic cell transplantation. Conditioning will consist of fludarabine, melphalan, and thiotepa. Graft versus host disease prophylaxis will be with post-transplant cyclophosphamide in addition to standard tacrolimus and mycophenolate mofetil. Donors will undergo HLA and KIR geno- and allotyping to determine the best donor.
melphalan: melphalan (140 mg/m2 IV on day -7)
fludarabine: fludarabine (40 mg/m2/d on days -5 through -2)
thiotepa: thiotepa (5 mg/kg IV on day -67)
Cyclophosphamide: cyclophosphamide (50 mg/kg IV on day +3 and +4)
Mesna
Mycophenolate Mofetil: (15 mg/kg PO/IV TID)
Filgrastim
Tacrolimus
Deaths Number Affected:
17
Deaths Number At Risk:
None
Serious Number Affected:
10
Serious Number At Risk:
44
Other Number Affected:
43
Other Number At Risk:
44
Study:
NCT02880293
Results Section:
NCT02880293
Adverse Events Module:
NCT02880293